Tourette Syndrome
A solid 2023 RCT and a 2024 meta-analysis show real tic reduction — with cognitive side effects in some people.
Neurology Emerging
What the research says
Tourette's is emerging as one of the better-evidenced uses. A 2023 double-blind, randomized, placebo-controlled crossover trial (22 adults with severe Tourette's) tested an oral 1:1 THC:CBD oil titrated up to 20 mg/day of each. Tic score (YGTSS) dropped by 8.9 points on active treatment versus 2.5 on placebo — a significant interaction, comparable in magnitude to antipsychotic treatment. Tic reduction was confirmed by blinded video raters, and obsessive-compulsive symptoms and anxiety also improved.
A 2024 systematic review and meta-analysis of 9 studies (401 patients) reinforced this: cannabinoids significantly reduced tic severity (Yale Global Tic Severity Scale and Premonitory Urge to Tics scores) versus placebo, though effects on obsessive-compulsive scores didn't reach significance. The most common side effect in the RCT was cognitive: slowed mentation, memory lapses, and poor concentration — in a third of participants.
The honest caveats
The 2023 trial is strong methodologically but small and single-site, and cognitive side effects are a genuine cost for a condition that often coexists with attention and learning issues. There's also no long-term data on tolerance — the anti-tic effect may fade. Current guidelines still consider this investigational; the 2024 meta-analysis explicitly calls for larger placebo-controlled trials before firm recommendations.
Compounds to explore
These are the compounds — terpenes and cannabinoids — that the research connects to this condition. They are starting points for reading a COA or choosing a product, not prescriptions. Each has its own guide with more detail.